Toggle navigation
ABOUT US
Overview
Leadership
Governance
Board
Our purpose
Global footprint
Our global reach
Partners
Press releases
News
Our science
Drug optimization
Lauriad
®
technology
Overview
How it works
Scientific publications
Lauriad
®
applications
OUR MEDICINES
PIPELINE
Commercialized medicines
Sitavig
®
Loramyc
®
PARTNER WITH US
Commercial & Industrial partners
Academic & Research collaborations
Careers
Working at Vectans Pharma
Join us
CONTACT
Press releases
March 2023
Exclusive agreement with the Menarini group and Berlin Chemie for Sitavig®
Read the press release
September 2022
Exclusive agreement with Berlin Chemie for Sitavig
®
in Eastern Europe and the CIS region
Read the press release
August 2022
Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®
Read the press release
March 2022
Nomination of François Boutignon as Chief Innovation and Technology Officer
Read the press release
January 2021
China approves commercialization for Oravig
®
Read the press release
February 2020
Exclusive licensing agreement with m8 Pharmaceuticals
Read the press release
230 Bureaux de la colline
92213 Saint-Cloud
France
contact@vectans.com
FOLLOW US
Copyright © VECTANS PHARMA
Legal notices and privacy policy
